Published in Blood on August 15, 1995
EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res (2008) 2.46
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol (2008) 1.29
Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol (2000) 1.26
Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 1.24
Hodgkin's disease and the Epstein-Barr virus. Mol Pathol (2000) 1.15
Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One (2007) 1.07
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood (2013) 1.02
Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer (1997) 0.98
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica (2010) 0.98
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J Virol (2000) 0.98
Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer (2001) 0.85
Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer (1999) 0.84
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol (2012) 0.80
Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study. PLoS One (2016) 0.75
Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma. Mol Clin Oncol (2015) 0.75
Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol (2015) 0.75
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
Antibodies specific for the carboxy- and amino-terminal regions of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A (1980) 4.04
Ultrastructural features of Mycoplasma pneumoniae. J Bacteriol (1970) 3.84
A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med (1995) 3.30
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol (1999) 2.80
HLA class II allelic variation and susceptibility to pemphigus vulgaris. Proc Natl Acad Sci U S A (1988) 2.72
Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol (2000) 2.56
ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 2.38
The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol (2000) 2.36
Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science (1988) 2.30
Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol (1978) 2.29
Morbidity of 10 110 hysterectomies by type of approach. Hum Reprod (2001) 2.28
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst (1999) 2.18
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol (2001) 2.13
Overexpression of folate binding protein in ovarian cancers. Int J Cancer (1997) 2.13
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Antibiotic prophylaxis for hysterectomy, a prospective cohort study: cefuroxime, metronidazole, or both? BJOG (2013) 2.00
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med (1999) 1.98
HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol (1986) 1.88
Intracerebral inflammation after human brain contusion. Neurosurgery (1998) 1.82
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens (2007) 1.77
Specifically cytotoxic lymphocytes produced by preincubation with antibody-complexed target cells. J Immunol (1972) 1.74
Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol (1997) 1.72
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol (2006) 1.71
Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. Int J Cancer (1997) 1.65
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS (2001) 1.64
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst (2001) 1.63
Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood (1994) 1.58
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
The xanthogranulomatous process. Xanthogranulomatous inflammation. Pathol Res Pract (1988) 1.55
HLA polymorphism in Israel. 9. An overall comparative analysis. Tissue Antigens (1978) 1.54
Urinary tract injuries after hysterectomy. Obstet Gynecol (1998) 1.53
Genetic variation of three tetrameric tandem repeats in four distinct Israeli ethnic groups. J Forensic Sci (1999) 1.53
Discordant HHV8 detection in a young HIV-negative patient with Kaposi's sarcoma and sarcoidosis. Clin Infect Dis (2001) 1.52
Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet (1999) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. Crit Care Med (1999) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Tumor-induced immune dysfunction. Cancer Immunol Immunother (1999) 1.47
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
Uropod formation in phytohaemagglutinin (PHA) stimulated lymphocytes. Exp Cell Res (1971) 1.47
Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. J Infect Dis (1997) 1.47
Metastasizing dermal squamomelanocytic tumour: more evidences. J Eur Acad Dermatol Venereol (2011) 1.46
Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. Am J Obstet Gynecol (2000) 1.45
Medium tumor antigen of polyomavirus transformation-defective mutant NG59 is associated with 73-kilodalton heat shock protein. J Virol (1987) 1.43
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Occupation and soft-tissue sarcoma in northeastern Italy. Cancer Causes Control (1992) 1.41
No HLA antigen is significant in classic Kaposi's sarcoma. J Am Acad Dermatol (1993) 1.39
Expression of natural killer antigens in a subset of 'non-T, non-B lymphoma/leukaemia with histiocytic features'. Br J Haematol (1990) 1.39
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases. AIDS (1989) 1.38
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
MALA-2, mouse homologue of human adhesion molecule ICAM-1 (CD54). Eur J Immunol (1989) 1.37
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer (1998) 1.36
Immunohistopathology of lymph nodes in HTLV-III infected homosexuals with persistent adenopathy or AIDS. Cancer Res (1985) 1.36
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood (1999) 1.35
Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). Int J Cancer (1988) 1.34
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 1.31
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens (2004) 1.31
Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost (2006) 1.30
Grades of recommendation for antithrombotic agents. Chest (1998) 1.30
High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene (1992) 1.30
Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res (1993) 1.29
Phosphorylation of threonine in the proline-rich carboxy-terminal region of simian virus 40 large T antigen. J Virol (1981) 1.29
A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science (1988) 1.28
Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res (1999) 1.28
Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. Br J Dermatol (2004) 1.27
Purified polyoma virus medium T antigen has tyrosine-specific protein kinase activity but no significant phosphatidylinositol kinase activity. Mol Cell Biol (1986) 1.27
Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev (2000) 1.26
Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol (2001) 1.25
Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res (1997) 1.25
DNA damage induced by auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (alkaline elution assay and SCE induction). J Toxicol Environ Health (1982) 1.24
Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis (1994) 1.24
The major histocompatibility complex-restricted antigen receptor on T cells: the genetics of expression of an allotype. J Immunol (1985) 1.24
Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum (1998) 1.24
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia (1998) 1.23
The distribution of HLA on human lymphoid, bone marrow and peripheral blood cells. Eur J Immunol (1979) 1.23
Morphological observations on the cytotoxicity of human bood lymphocytes for antibody-coated chicken erythrocytes. Exp Cell Res (1970) 1.22
Increased occurrence of cytoplasmic filaments in in vitro propagated rat liver epithelial cells. Exp Cell Res (1965) 1.22
Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. J Med Virol (1995) 1.22
An immunohistological study of human lymphoma. Clin Exp Immunol (1980) 1.21
Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. Acta Pathol Microbiol Immunol Scand A (1987) 1.21
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Dietary factors and non-Hodgkin's lymphoma: a case-control study in the northeastern part of Italy. Nutr Cancer (1989) 1.21
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20